PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells

Clinical and Experimental Pharmacology and Physiology

Volumn 42, Issue 12, 2015, Pages 1317-1326

  Chen, Jiezhong ^a   Shao, Renfu ^b   Li, Feng ^c   Monteiro, Michael ^a   Liu, Jun Ping ^d   Xu, Zhi Ping ^a   Gu, Wenyi ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF THE SUNSHINE COAST   (Australia)

^c SHIHEZI UNIVERSITY   (China)

^d HANGZHOU NORMAL UNIVERSITY   (China)

Author keywords

BEZ235; Cancer stem cells; CD133; CD24; CD44; Colon cancer HCT 116; Lgr5; PI3K Akt; Stemness

Indexed keywords

CD133 ANTIGEN; CD24 ANTIGEN; DACTOLISIB; HERMES ANTIGEN; INSULIN; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUINOLINE DERIVATIVE; TARGET OF RAPAMYCIN KINASE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURVIVAL; CELL ISOLATION; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; HCT116 CELL LINE; HUMAN; HUMAN CELL; SIGNAL TRANSDUCTION; STEM CELL CULTURE; CELL SURVIVAL; COLON TUMOR; DRUG EFFECTS; DRUG RESISTANCE; HCT 116 CELL LINE; METABOLISM; METASTASIS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CELL SURVIVAL; COLONIC NEOPLASMS; DRUG RESISTANCE, NEOPLASM; HCT116 CELLS; HUMANS; IMIDAZOLES; INSULIN; NEOPLASM METASTASIS; NEOPLASTIC STEM CELLS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84949961127     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/1440-1681.12493     Document Type: Article

References (58)

1. Aoki K, Tamai Y, Horiike S, Oshima M, Taketo MM. Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Δ716 Cdx2 + /- compound mutant mice. Nature Genet. 2003; 35: 323-30.
2. Catalano V, Di Franco S, Iovino F, Dieli F, Stassi G, Todaro M. CD133 as a target for colon cancer. Expert Opin. Ther. Targets 2012; 16: 259-67.
3. Davies JM, Goldberg RM. Treatment of metastatic colorectal cancer. Semin. Oncol. 2011; 38: 552-60.
4. Chen J, Huang X-F, Qiao L, Katsifis A. Insulin caused drug resistance to oxaliplatin in colon cancer cell line HT29. Journal of Gastrointestinal Oncology 2011; 2: 27.
5. Dallas NA, Xia L, Fan F et al. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res. 2009; 69: 1951-7.
6. Dandawate P, Padhye S, Ahmad A, Sarkar FH. Novel strategies targeting cancer stem cells through phytochemicals and their analogs. Drug Deliv. Translat. Res. 2013; 3: 165-82.
7. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J. Clin. Investig. 2010; 120: 41-50.
8. G-h Rao, H-m Liu, B-w Li et al. Establishment of a human colorectal cancer cell line P6C with stem cell properties and resistance to chemotherapeutic drugs. Acta Pharmacol. Sinica 2013; 34: 793-804.
9. Kozovska Z, Gabrisova V, Kucerova L. Colon cancer: Cancer stem cells markers, drug resistance and treatment. Biomed. Pharmacother. 2014; 68: 911-6.
10. Schneider M, Huber J, Hadaschik B, Siegers GM, Fiebig HH, Schuler J. Characterization of colon cancer cells: a functional approach characterizing CD133 as a potential stem cell marker. BMC Cancer 2012; 12: 96-107.
11. Chen X, Wei B, Han X et al. LGR5 is required for the maintenance of spheroid-derived colon cancer stem cells. Int. J. Mol. Med. 2014; 34: 35-42.
12. Kobayashi S, Yamada-Okabe H, Suzuki M et al. LGR5-positive colon cancer stem cells interconvert with drug-resistant LGR5-negative cells and are capable of tumor reconstitution. Stem Cells 2012; 30: 2631-44.
13. de Sousa EM, Vermeulen L, Richel D, Medema JP. Targeting Wnt signaling in colon cancer stem cells. Clin. Cancer Res. 2011; 17: 647-53.
14. Sikandar SS, Pate KT, Anderson S et al. NOTCH signaling is required for formation and self-renewal of tumor-initiating cells and for repression of secretory cell differentiation in colon cancer. Cancer Res. 2010; 70: 1469-78.
15. Chen J. Potential value and limitation of dual inhibitors of PI3K and mTOR in the treatment of cancer. Curr. Cancer Drug Targets 2013; 13: 117-20.
16. Bu Z, Ji J. Therapeutic implications of mTOR inhibitors in the treatment of gastric cancer. Curr. Cancer Drug Targets 2013; 13: 121-5.
17. Cho DC, Mier JW. Dual inhibition of PI3-kinase and mTOR in renal cell carcinoma. Curr. Cancer Drug Targets 2013; 13: 126-42.
18. Elfiky AA, Jiang Z. The PI3 kinase signaling pathway in prostate cancer. Curr. Cancer Drug Targets 2013; 13: 157-64.
19. Chen J, Iverson D. Estrogen in obesity-associated colon cancer: Friend or foe? Protecting postmenopausal women but promoting late-stage colon cancer. Cancer Causes Control 2012; 23: 1767-73.
20. Page C, Lin HJ, Jin Y et al. Overexpression of Akt/AKT can modulate chemotherapy-induced apoptosis. Anticancer Res. 2000; 20: 407-16.
21. Brognard J, Clark AS, Ni Y, Dennis PA. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 2001; 61: 3986-97.
22. Chen J, Katsifis A, Hu C, Huang X-F. Insulin decreases therapeutic efficacy in colon cancer cell line HT29 via the activation of the PI3K/Akt pathway. Curr. Drug Discov. Technol. 2011; 8: 119-25.
23. Maira S-M, Stauffer F, Brueggen J et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Molec. Cancer Therapeut. 2008; 7: 1851-63.
24. Roper J, Richardson MP, Wang WV et al. The dual PI3K/mTOR inhibitor NVP-BEZ235 induces tumor regression in a genetically engineered mouse model of PIK3CA wild-type colorectal cancer. PLoS ONE 2011; 6: e25132.
25. Dubrovska A, Kim S, Salamone RJ et al. The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc. Natl Acad. Sci. USA 2009; 106: 268-73.
26. Dubrovska A, Elliott J, Salamone RJ et al. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin. Cancer Res. 2010; 16: 5692-702.
27. Kanai R, Wakimoto H, Martuza RL, Rabkin SD. A novel oncolytic herpes simplex virus that synergizes with phosphoinositide 3-kinase/Akt pathway inhibitors to target glioblastoma stem cells. Clin. Cancer Res. 2011; 17: 3686-96.
28. Wu S, Wang X, Chen J, Chen Y. NVP-BEZ235, a novel dual PI3K/mTOR inhibitor, enhances the radiosensitivity of human glioma stem cells in vitro. Acta Pharmacol. Sinica 2013; 34: 681-90.
29. Sunayama J, Sato A, Matsuda K et al. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neurol. Oncol. 2010; 12: 1205-19.
30. Vermeulen L, Todaro M, de Sousa Mello F et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc. Natl Acad. Sci. USA 2008; 105: 13427-32.
31. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 2003; 100: 3983-8.
32. Gu W, Yeo E, McMillan N, Yu C. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Ther. 2011; 18: 897-905.
33. Chen J. Multiple signal pathways in obesity-associated cancer. Obesity Rev. 2011; 12: 1063-70.
34. Chen J. The Src/PI3K/Akt signal pathway may play a key role in decreased drug efficacy in obesity-associated cancer. J. Cellul. Biochem. 2010; 110: 279-80.
35. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10.
36. Todaro M, Alea MP, Di Stefano AB et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
37. Boman BM, Huang E. Human colon cancer stem cells: A new paradigm in gastrointestinal oncology. J. Clin. Oncol. 2008; 26: 2828-38.
38. Ricci-Vitiani L, Lombardi DG, Pilozzi E et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-5.
39. Raza U, Zhang JD, Sahin O. MicroRNAs: Master regulators of drug resistance, stemness, and metastasis. J. Mol. Med. (Berlin) 2014; 92: 321-36.
40. Liu YS, Hsu HC, Tseng KC, Chen HC, Chen SJ. Lgr5 promotes cancer stemness and confers chemoresistance through ABCB1 in colorectal cancer. Biomed. Pharmacother. 2013; 67: 791-9.
41. Hasegawa S, Eguchi H, Nagano H et al. MicroRNA-1246 expression associated with CCNG2-mediated chemoresistance and stemness in pancreatic cancer. Br. J. Cancer 2014; 111: 1572-80.
42. Kinugasa Y, Matsui T, Takakura N. CD44 expressed on cancer-associated fibroblasts is a functional molecule supporting the stemness and drug resistance of malignant cancer cells in the tumor microenvironment. Stem Cells 2014; 32: 145-56.
43. Seguin L, Kato S, Franovic A et al. An integrin beta(3)-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition. Nat. Cell Biol. 2014; 16: 457-68.
44. Cai Z, Ke J, He X et al. Significance of mTOR signaling and its inhibitor against cancer stem-like cells in colorectal cancer. Ann. Surg. Oncol. 2014; 21: 179-88.
45. Johnston PG, Lenz H-J, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. 1995; 55: 1407-12.
46. Copur S, Aiba K, Drake JC, Allegra CJ, Chu E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. Biochem. Pharmacol. 1995; 49: 1419-26.
47. Bartucci M, Svensson S, Ricci-Vitiani L et al. Obesity hormone leptin induces growth and interferes with the cytotoxic effects of 5-fluorouracil in colorectal tumor stem cells. Endocr. Relat. Cancer 2010; 17: 823-33.
48. Chen Y, Wang Z, Chang P et al. The effect of focal adhesion kinase gene silencing on 5-fluorouracil chemosensitivity involves an Akt/NF-kappaB signaling pathway in colorectal carcinomas. Int. J. Cancer 2010; 127: 195-206.
49. Chen J. Is Src the key to understanding metastasis and developing new treatments for colon cancer? Nature Clin. Prac. Gastroenterol. Hepatol. 2008; 5: 306-7.
50. Chen J. Targeted therapy of obesity-associated colon cancer. Translat. Gastrointest. Cancer 2011; 1: 44-57.
51. Huang XF, Chen JZ. Obesity, the PI3K/Akt signal pathway and colon cancer. Obesity Rev. 2009; 10: 610-6.
52. Chen KL, Pan F, Jiang H et al. Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells. Clin. Exp. Metastasis 2011; 28: 751-63.
53. Shmelkov SV, Butler JM, Hooper AT et al. CD133 expression is not restricted to stem cells, and both CD133 + and CD133- metastatic colon cancer cells initiate tumors. J. Clin. Invest. 2008; 118: 2111-20.
54. Bellizzi A, Sebastian S, Ceglia P et al. Co-expression of CD133(+)/CD44(+) in human colon cancer and liver metastasis. J. Cell. Physiol. 2013; 228: 408-15.
55. Haraguchi N, Ohkuma M, Sakashita H et al. CD133 + CD44 + population efficiently enriches colon cancer initiating cells. Ann. Surg. Oncol. 2008; 15: 2927-33.
56. Merlos-Suarez A, Barriga FM, Jung P et al. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell 2011; 8: 511-24.
57. Hirsch D, Barker N, McNeil N et al. LGR5 positivity defines stem-like cells in colorectal cancer. Carcinogenesis 2014; 35: 849-58.
58. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Meth. Cell Biol. 2008; 86: 311-24.